Events

Resilient Health Systems for Cancer - Joint event Mission Adaptation and Mission Cancer
APR
Wed
30
14:00 - 15:30

This was 4 months ago

Location

Online

Programmes
Missions

Experts and stakeholders from the EU Mission Adaptation to Climate Change and the EU Mission Cancer will come together to share knowledge on the connections between climate change and cancer.

Participants will gain insights into strategies for adapting healthcare systems and infrastructure to withstand climate hazards.

The session will encourage collaboration on building resilient healthcare systems that can effectively address cancer care in a changing climate.

For more information on this event and to register, please visit this event page

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Event calendar

 

Testimonial

image of Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.